Aclaris Therapeutics Inc (NASDAQ:ACRS)’s traded shares stood at 0.77 million during the last session, with the company’s beta value hitting 0.46. At the close of trading, the stock’s price was $3.94, to imply an increase of 3.41% or $0.13 in intraday trading. The ACRS share’s 52-week high remains $5.17, putting it -31.22% down since that peak but still an impressive 79.7% since price per share fell to its 52-week low of $0.80. The company has a valuation of $281.44M, with an average of 1.53 million shares in intraday trading volume over the past 10 days and average of 2.21 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Aclaris Therapeutics Inc (ACRS), translating to a mean rating of 1.57. Of 4 analyst(s) looking at the stock, 1 analyst(s) give ACRS a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.28.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Aclaris Therapeutics Inc (NASDAQ:ACRS) trade information
After registering a 3.41% upside in the last session, Aclaris Therapeutics Inc (ACRS) has traded red over the past five days. The 5-day price performance for the stock is -3.19%, and 74.34% over 30 days. With these gigs, the year-to-date price performance is 275.24%. Short interest in Aclaris Therapeutics Inc (NASDAQ:ACRS) saw shorts transact 1.56 million shares and set a 1.43 days time to cover.
The extremes give us $3 and $8 for target low and target high price respectively. As such, ACRS has been trading -103.05% off suggested target high and 23.86% from its likely low.
Aclaris Therapeutics Inc (ACRS) estimates and forecasts
Looking at statistics comparing Aclaris Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Aclaris Therapeutics Inc (ACRS) shares are 290.10% up over the last 6 months, with its year-to-date growth rate higher than industry average at 51.61% against 16.60%. The rating firms project that company’s revenue will shrink -49.47% compared to the previous financial year.
Revenue forecast for the current quarter as set by 8 analysts is 5.85M. Meanwhile, for the current quarter, a total of 4 analyst(s) estimate revenue growth to 3.25M.Earnings reports from the last fiscal year show that sales brought in 17.57M and 2.4M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -66.73% before jumping 35.69% in the following quarter.
ACRS Dividends
Aclaris Therapeutics Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Aclaris Therapeutics Inc (NASDAQ:ACRS)’s Major holders
Aclaris Therapeutics Inc insiders hold 3.60% of total outstanding shares, with institutional holders owning 90.26% of the shares at 93.64% float percentage. In total, 90.26% institutions holds shares in the company, led by BML CAPITAL MANAGEMENT, LLC. As of 2024-06-30, the company held over 12.99 million shares (or 18.2739% of shares), all amounting to roughly $14.29 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 4.69 million shares, or about 6.5952% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $5.16 million.
